NCT06868381 is a Phase 2 clinical trial of Baricitinib (LY3009104) 4 mg in Cardiac Sarcoidosis, sponsored by Stanford University.

Who is sponsoring NCT06868381?

NCT06868381 is sponsored by Stanford University.

What drugs are being tested in NCT06868381?

Interventions in NCT06868381: Baricitinib (LY3009104) 4 mg.

What condition does NCT06868381 study?

NCT06868381 studies Cardiac Sarcoidosis.

Is NCT06868381 still recruiting?

NCT06868381 is currently not yet recruiting. Last updated 10 February 2026.

Last reviewed 2026-02-10 · How we verify

NCT06868381

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Trial of Baricitinib in Patients With Cardiac Sarcoidosis

Not yet recruiting Phase 2 Last updated 10 February 2026

What this trial tests

Phase 2 trial testing Baricitinib (LY3009104) 4 mg in Cardiac Sarcoidosis in 10 participants. Not yet recruiting.

Timeline

1 April 2026

Primary endpoint
1 July 2028

1 December 2028

Quick facts

Lead sponsor	Stanford University
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	1 April 2026
Primary completion	1 July 2028
Estimated completion	1 December 2028
Sites	1 location across United States

Drugs / interventions tested

Baricitinib (LY3009104) 4 mg — full drug profile →

Conditions studied

Cardiac Sarcoidosis — all drugs for Cardiac Sarcoidosis →

Sponsor

Stanford University

Who can join

Adults 18 to 85, any sex, with Cardiac Sarcoidosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to learn if baricitinib in combination with a background steroid-sparing medication can treat active cardiac sarcoidosis in adults. The main question it aims to answer is: \- In patients with active cardiac sarcoidosis, does treatment with baricitinib improve cardiac sarcoidosis disease activity as assessed by changes on cardiac FDG-PET/CT? Participants will: * Take baricitinib in combination with a steroid-sparing therapy for up to 16 weeks * Visit the clinic every two to four weeks for checkups and tests * Be asked to complete questionnaires to see how they feel on baricitinib and medication diaries to record when they take baricitinib

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Cardiovascular Manifestations and Immunobiology of Sarcoidosis.
Weintraub NL, Guha A, Taskar V, Elam RE, et al · · 2026 · PMID 41410048 · DOI 10.1161/atvbaha.125.323111

Verify or expand the search:

Other trials of Baricitinib (LY3009104) 4 mg

Trials testing the same drug.

NCT06687551 — JAK Inhibitor Dose TAPering Strategy Study · Phase 4 · not yet recruiting
NCT05188521 — Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus · Phase 2 · completed

Other recruiting trials for Cardiac Sarcoidosis

Currently open trials in the same condition.

NCT07159074 — Repurposing Tilmanocept for Cardiac Sarcoidosis · Phase 2 · recruiting
NCT05954507 — Evaluation of the Prognostic Value of PET/MRI in Cardiac Sarcoidosis · NA · recruiting
NCT06510894 — Diagnostic Utility of SGLT1/2 Inhibition to Facilitate Myocardial Glucose Suppression · recruiting
NCT06409585 — Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis Transition · recruiting
NCT04737317 — Diagnostic Criteria in Cardiac Sarcoidosis · recruiting

Other Stanford University trials

Trials by the same sponsor.

NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
NCT04225949 — Patients Understanding of PROM Graphs · NA · withdrawn
NCT06273098 — School-Based Bladder Health Intervention · NA · withdrawn
NCT04652635 — Management of Nailbed Injuries · NA · withdrawn
NCT05443503 — Stanford Spine Keeper - Managing Your Low Back Pain · NA · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06868381 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Stanford University
Last refreshed: 10 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06868381.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing